Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 1]

View source ↗

Summary

Phase 1 trial of Yttrium-90 ibritumomab tiuxetan (Zevalin) for Waldenström's macroglobulinemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Lymphoma | Phase 1 | Status: TERMINATED